Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms

Ann Oncol. 2012 Jul;23(7):1928. doi: 10.1093/annonc/mds166.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Everolimus
  • Humans
  • Indoles / therapeutic use
  • Neuroendocrine Tumors / classification*
  • Neuroendocrine Tumors / drug therapy
  • Neuroendocrine Tumors / pathology
  • Pancreatic Neoplasms / classification*
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / pathology
  • Pyrroles / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Sunitinib
  • World Health Organization*

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Everolimus
  • Sunitinib
  • Sirolimus